Apple Podcasts or Listen Here

We are bringing you near-daily updates on COVID-19. There is a firehose of information and most of us are too busy to read and digest it all. Note: If you are listening to these more than a few days in the future, please beware that information may have changed and check subsequent episodes. This episode was recorded August 24, 2020.

Convalescent plasma has been a potential therapy for COVID-19. We covered the basics in this post, an RCT (Li et al) in this post. Here we discuss the US experience to date, which, despite detailing >35,000 patients who received plasma, did not randomize patients.

Apple Podcasts or Listen Here

We are bringing you near-daily updates on COVID-19. There is a firehose of information and most of us are too busy to read and digest it all. Note: If you are listening to these more than a few days in the future, please beware that information may have changed and check subsequent episodes. This episode was recorded August 23, 2020.

Remdesivir, an inhibitor of viral RNA-dependent RNA polymerase, has been investigated for COVID-19. We have previously covered the initial uncontrolled report, the ACTT-1 trial, and a trial of 5-days vs 10 days of remdesivir which showed no difference. Here we have another trial by Spinnner et al in JAMA 2020.